Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 4/20 | 0.41 |
| ▸ | MAOB | P27338 | 4/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.40 |
| ▸ | TUBB | P07437 | 1/20 | 0.40 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.40 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.40 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.40 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.40 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.40 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.40 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.40 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11461839 | 0.93 | HSD17B1 (0.49) | HSD17B1MEN1KMT2AMAPK1NPSR1 | |
| SCHEMBL30558410 | 0.93 | HSD17B1 (0.49) | HSD17B1MEN1KMT2AMAPK1NPSR1 | |
| SCHEMBL25369104 | 0.90 | HSD17B1 (0.46) | HSD17B1MEN1KMT2AMAPK1NPSR1 | |
| SCHEMBL606742 | 0.90 | PTGS2 (0.47) | HSD17B1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL424613 | 0.86 | HSD17B1 (0.54) | HSD17B1MEN1KMT2AMAPK1NPSR1 | |
| SCHEMBL3972786 | 0.83 | TUBB4A (0.46) | HSD17B1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL9621112 | 0.82 | KMT2A (0.53) | HSD17B1MEN1KMT2AMAPK1NPSR1 | |
| SCHEMBL9621080 | 0.82 | KMT2A (0.53) | HSD17B1MEN1KMT2AMAPK1NPSR1 | |
| SCHEMBL2776025 | 0.81 | HSD17B1 (0.50) | HSD17B1MEN1KMT2AMAPK1NPSR1 | |
| SCHEMBL28633834 | 0.81 | HSD17B1 (0.50) | HSD17B1MEN1KMT2AMAPK1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE48156-E1 | Electronic device comprising an organic semiconducting material | NOVALED GMBH (DE) | 2020-08-11 | — | — | US | disclosed |
| EP-3561876-A1 | DISPLAY | Novaled GmbH (DE) | 2019-10-30 | — | — | EP | disclosed |
| EP-2786435-B1 | Compounds | NOVALED GMBH (DE) | 2019-07-17 | — | — | EP | disclosed |
| US-10323043-B2 | Derivatives of macrocyclic N-aryl-tricyclopyrimidine-2-amine polyethers as inhibitors of FTL3 and JAK | PIERRE FABRE MEDICAMENT (FR) | 2019-06-18 | — | — | US | disclosed |
| US-20170283432-A1 | DERIVATIVES OF MACROCYCLIC N-ARYL-TRICYCLOPYRIMIDINE-2-AMINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK | PIERRE FABRE MEDICAMENT (FR) | 2017-10-05 | — | — | US | disclosed |
| US-9722183-B2 | Display | NOVALED GMBH (DE) | 2017-08-01 | — | — | US | disclosed |
| US-9040175-B2 | Electronic device comprising an organic semiconducting material | NOVALED AG (DE) | 2015-05-26 | — | — | US | disclosed |
| US-20140332790-A1 | Display | NOVALED GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-20140243334-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20130200341-A1 | Electronic Device Comprising an Organic Semiconducting Material | NOVALED AG (DE) | 2013-08-08 | — | — | US | disclosed |
| WO-2012012320-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENIUM PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012012320-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENIUM PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283432-A1 | DERIVATIVES OF MACROCYCLIC N-ARYL-TRICYCLOPYRIMIDINE-2-AMINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK | JAK2, JAK3, JAK1 | HSD17B1 4253/4885MEN1 792/4885KMT2A 1010/4885 |
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | HSD17B1 482/4885MEN1 3294/4885KMT2A 41/4885 |
| US-10323043-B2 | Derivatives of macrocyclic N-aryl-tricyclopyrimidine-2-amine polyethers as inhibitors of FTL3 and JAK | JAK2, JAK3, JAK1 | HSD17B1 4253/4885MEN1 792/4885KMT2A 1010/4885 |
| US-20140243334-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | HDAC6, H1-3, H1-5 | HSD17B1 461/4885MEN1 3777/4885KMT2A 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.